Ferguson Wellman Capital Management Inc. Has $3.65 Million Position in Abbott Laboratories $ABT

Ferguson Wellman Capital Management Inc. lessened its position in shares of Abbott Laboratories (NYSE:ABT) by 77.2% in the second quarter, HoldingsChannel.com reports. The fund owned 40,171 shares of the healthcare product maker’s stock after selling 136,385 shares during the period. Ferguson Wellman Capital Management Inc.’s holdings in Abbott Laboratories were worth $3,645,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in ABT. Nissay Asset Management Corp Japan raised its position in Abbott Laboratories by 2.1% during the second quarter. Nissay Asset Management Corp Japan now owns 231,778 shares of the healthcare product maker’s stock valued at $21,032,000 after purchasing an additional 4,797 shares in the last quarter. Chapin Davis Inc. boosted its holdings in shares of Abbott Laboratories by 11.4% in the 2nd quarter. Chapin Davis Inc. now owns 5,466 shares of the healthcare product maker’s stock valued at $496,000 after purchasing an additional 558 shares in the last quarter. Tandem Capital Management Corp ADV boosted its holdings in shares of Abbott Laboratories by 5.6% in the 2nd quarter. Tandem Capital Management Corp ADV now owns 30,998 shares of the healthcare product maker’s stock valued at $2,813,000 after purchasing an additional 1,655 shares in the last quarter. Field & Main Bank bought a new position in shares of Abbott Laboratories in the 2nd quarter valued at $652,000. Finally, Archer Investment Corp acquired a new position in shares of Abbott Laboratories during the 2nd quarter worth $309,000. 75.18% of the stock is owned by institutional investors.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott shares outperformed the broader market in the latest session, suggesting continued investor support for the diversified healthcare-products company. The move adds to its gains above both its 50-day and 200-day moving averages. Abbott Exceeds Market Returns: Some Facts to Consider
• Neutral Sentiment: A separate market comparison reported that Abbott underperformed its competitors during Tuesday’s trading session. The article did not identify a company-specific operational problem, making the relative weakness more relevant to short-term sentiment than to Abbott’s long-term fundamentals. Abbott Laboratories Stock Underperforms Tuesday
• Neutral Sentiment: Vice President John McCoy Jr. sold 27 shares for approximately $2,958. The transaction reduced his direct holdings by only 0.11%, leaving him with 24,549 shares, so it is too small to represent a meaningful change in insider conviction. SEC Insider Transaction Filing
• Neutral Sentiment: An investor-focused healthcare article mentioned Abbott primarily as the former parent of AbbVie, rather than discussing new developments at ABT. It therefore provides little direct information about Abbott’s near-term earnings or valuation. Abbott Laboratories Company Information

Analyst Upgrades and Downgrades

Several analysts recently weighed in on ABT shares. Piper Sandler reaffirmed an “overweight” rating and issued a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Wells Fargo & Company increased their target price on shares of Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. Robert W. Baird initiated coverage on shares of Abbott Laboratories in a report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price target on the stock. Bank of America lowered their price objective on shares of Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $130.00 target price on shares of Abbott Laboratories in a research report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $119.50.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $108.81 on Friday. The stock’s 50-day moving average is $104.14 and its 200-day moving average is $100.06. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The stock has a market cap of $188.28 billion, a P/E ratio of 35.21, a price-to-earnings-growth ratio of 2.05 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same period last year, the company earned $1.26 EPS. The firm’s revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities research analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were paid a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s payout ratio is currently 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.